A federal judge has dismissed part of a lawsuit brought by Eli Lilly against Empower Pharmacy, marking a partial setback in the company’s effort to challenge the sale of compounded versions of its GLP-1 drugs. 

The Supreme Court of the United States has heard oral arguments in the ongoing dispute between Hikma Pharmaceuticals and Amarin Pharma, focusing on the legal boundaries of marketing generic drugs under a “skinny label.” 

An update in the ongoing opioid litigation involving Purdue Pharma shows that the state of Oregon is set to receive $65.6 million as part of a wider $7.4 billion settlement linked to the opioid crisis. 

The High Court in Kuala Lumpur has dismissed an application by Techno Secure Print Sdn Bhd seeking permission to initiate judicial review proceedings against the Health Ministry over a terminated pharmaceutical tender.

The Supreme Court of the United States is set to hear a case that could affect how quickly lower-cost generic drugs reach patients. The dispute, known as Hikma v. Amarin, involves Hikma Pharmaceuticals and Amarin over a heart disease drug called Vascepa.

Pharmaceutical company Merz has secured a key legal victory in its ongoing dispute over its multiple sclerosis drug Fampyra. The Court of Appeal of the Unified Patent Court (UPC) has overturned an earlier decision and granted a preliminary injunction against Viatris.

A federal court in North Dakota has ruled that a state law aimed at expanding access to discounted medications is unconstitutional.

In a recent development, Boehringer Ingelheim announced that its experimental obesity drug survodutide achieved an average weight loss of up to 16.6% in a Phase III clinical trial.

In a significant development in long-running opioid litigation, Purdue Pharma has been sentenced to pay $5.5 billion in fines and penalties following its 2020 guilty plea in connection with the marketing of its opioid drug, OxyContin.

It has been confirmed today that Pfizer settled with the final defendant, Hikma Pharmaceuticals.

Jazz Pharmaceuticals has secured priority review from US regulators for an expanded use of its targeted cancer therapy Ziihera, advancing the Dublin-headquartered group's bid to establish the drug as a frontline standard of care in HER2-positive gastric and gastroesophageal cancers — one of the more commercially significant unmet needs in oncology.

Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation in an all-cash deal valued at approximately $739mn, doubling the size of its biotech royalty portfolio and cementing its position as one of the dominant aggregators in a niche corner of the pharmaceutical industry that has attracted growing investor attention.

Catalyst Pharmaceuticals, the US rare-disease drug developer, has emerged as a potential acquisition target for Italy's Angelini Pharma, in the latest sign of how aggressively European drugmakers are scouring the US market for commercial-stage assets in orphan indications.

Update from the Vyndamax (tafamidis) trial: Hikma Pharmaceuticals, the holdout defendant, no longer appears to be challenging the validity of Pfizer’s patent.

Novartis has secured European Commission approval for Rhapsido, its oral chronic skin disease drug, broadening the geographic reach of one of the Swiss group's most strategically significant immunology launches and opening a new front in the increasingly competitive market for oral targeted therapies.

A wave of analyst downgrades has hit Terns Pharmaceuticals after Merck agreed to acquire the US biotech for $6.7bn, ending one of the most striking small-cap rallies of the past year and underlining the willingness of large pharmaceutical groups to pay heavily for differentiated oncology assets.

Nine of the world's largest pharmaceutical companies have been seated alongside UK government officials on a new oversight committee charged with implementing the US-UK pharmaceuticals trade agreement, in a sign of how heavily the Trump administration's drug pricing reset is reshaping the commercial environment for medicines on both sides of the Atlantic.

BREAKING - Pfizer (PFE) SETTLES Tafamidis suit with two of three defendants. Key question for analysts - how long will Pfizer’s patent protection last under the settlement? Based on available research, generics could be out of the market until 2033-2035. PFE BBIO ALNY

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at $6.3bn upfront, as the US drugmaker deepens its push into neuroscience and sleep-related disorders.

Shares in Ionis Pharmaceuticals have surged more than 150 per cent over the past year, prompting investors to reassess whether further upside remains or if much of the growth story is already priced in.